PT2069395E - Novos antigénios e anticorpos associados a adenocarcinoma ductal do pâncreas - Google Patents

Novos antigénios e anticorpos associados a adenocarcinoma ductal do pâncreas Download PDF

Info

Publication number
PT2069395E
PT2069395E PT07820692T PT07820692T PT2069395E PT 2069395 E PT2069395 E PT 2069395E PT 07820692 T PT07820692 T PT 07820692T PT 07820692 T PT07820692 T PT 07820692T PT 2069395 E PT2069395 E PT 2069395E
Authority
PT
Portugal
Prior art keywords
pda
antibodies
enoa
isoforms
ala
Prior art date
Application number
PT07820692T
Other languages
English (en)
Portuguese (pt)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Original Assignee
Ribovax Biotechnologies Sa
Bioline Diagnostici Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa, Bioline Diagnostici Srl filed Critical Ribovax Biotechnologies Sa
Publication of PT2069395E publication Critical patent/PT2069395E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
PT07820692T 2006-09-29 2007-09-28 Novos antigénios e anticorpos associados a adenocarcinoma ductal do pâncreas PT2069395E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06126726 2006-12-20

Publications (1)

Publication Number Publication Date
PT2069395E true PT2069395E (pt) 2012-04-27

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07820692T PT2069395E (pt) 2006-09-29 2007-09-28 Novos antigénios e anticorpos associados a adenocarcinoma ductal do pâncreas

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137832A2 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
IT1398782B1 (it) * 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2015106296A1 (en) 2014-01-13 2015-07-16 Berg Llc Enolse 1 (eno1) compositions and uses thereof
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
AU2007301966B2 (en) 2013-02-21
ES2381304T3 (es) 2012-05-25
AU2007301966A1 (en) 2008-04-03
KR20090094227A (ko) 2009-09-04
WO2008037792A1 (en) 2008-04-03
IL218442A0 (en) 2012-04-30
IL197868A0 (en) 2011-08-01
EA200970332A1 (ru) 2009-10-30
CA2664841A1 (en) 2008-04-03
ATE542831T1 (de) 2012-02-15
US8071721B2 (en) 2011-12-06
NZ576409A (en) 2012-02-24
IL197868A (en) 2013-03-24
JP2010505104A (ja) 2010-02-18
US20100028907A1 (en) 2010-02-04
BRPI0717282A2 (pt) 2013-10-15
EP2069395A1 (en) 2009-06-17
CN101578295B (zh) 2013-02-27
NO20091662L (no) 2009-06-29
PL2069395T3 (pl) 2012-06-29
DK2069395T3 (da) 2012-05-14
EA016731B1 (ru) 2012-07-30
EP2069395B1 (en) 2012-01-25
CN101578295A (zh) 2009-11-11

Similar Documents

Publication Publication Date Title
Suárez et al. CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells
Chu et al. Mapping Post-translational Modifications of the Histone Variant MacroH2A1 Using Tandem Mass Spectrometry* S
PT2069395E (pt) Novos antigénios e anticorpos associados a adenocarcinoma ductal do pâncreas
He et al. Phosphatidylethanolamine binding protein 4 (PEBP4) is a secreted protein and has multiple functions
Caballero et al. Chicken GRIFIN: a homodimeric member of the galectin network with canonical properties and a unique expression profile
Zhong et al. Identification of prohibitin 1 as a potential prognostic biomarker in human pancreatic carcinoma using modified aqueous two-phase partition system combined with 2D-MALDI-TOF-TOF-MS/MS
Naryzhny et al. Mechanistic Proteomic Profiling of High-grade Glioblastoma Using Virtual-experimental 2DE
Zawadzka et al. Variation and quantification among a target set of phosphopeptides in human plasma by multiple reaction monitoring and SWATH‐MS2 data‐independent acquisition
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
Semaan et al. Identification of potential glycoprotein biomarkers in estrogen receptor positive (ER+) and negative (ER-) human breast cancer tissues by LC-LTQ/FT-ICR mass spectrometry
Afshari et al. Glycoproteoforms of Osteoarthritis-associated Lubricin in Plasma and Synovial Fluid
Hazari et al. The endoplasmic reticulum stress sensor IRE1 regulates collagen secretion through the enforcement of the proteostasis factor P4HB/PDIA1 contributing to liver damage and fibrosis
Arielly et al. Quantitative analysis of caveolin-rich lipid raft proteins from primary and metastatic colorectal cancer clones
Vit et al. Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization
Fleron et al. Novel post-digest isotope coded protein labeling method for phospho-and glycoproteome analysis
Zurawel et al. Proteomic profiling of the mesenteric lymph after hemorrhagic shock: differential gel electrophoresis and mass spectrometry analysis
Cao et al. Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography
Mackay et al. Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma
WO2007020522A2 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
Dziadosz-Brzezińska et al. Considerations for antibody-based detection of NRF2 in human cells
Kübler et al. Phosphorylation of multifunctional galectins by protein kinases CK1, CK2, and PKA
Hintze et al. The ligand preference of LRP1 is regulated by O-glycans
San Francisco et al. Role of proteomics in the study of Trypanosoma cruzi biology
Akyildiz Demir et al. Identification of cytoplasmic sialidase NEU2-associated proteins by LC-MS/MS
Tian et al. LCN1 is highly expressed in cholangiocarcinoma patients and indicates poor prognosis